PC
OREX

Passport Capital’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Passport Capital’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-5,198
Closed -$407K – 295
2015
Q1 		$407K Buy
+5,198
New +$322K 0.01% 151
2013
Q4 		– Sell
-75,000
Closed -$4.6M – 205
2013
Q3 		$4.6M Hold
75,000
– – 0.15% 64
2013
Q2 		$4.38M Buy
+75,000
New +$4.61M 0.14% 80

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Passport Capital's OREX Position: Q2 2015 in Review

Passport Capital sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2015, closing a stake of 5,198 shares — an estimated $407K sold.

Passport Capital first reported a position in OREX in Q2 2013 and held it in 3 quarters. The position peaked at $4.6M in Q3 2013. 161 funds tracked by Wall St. Rank hold OREX as of Q2 2015.

  • Passport Capital reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • Passport Capital sold 5,198 Orexigen Therapeutics, Inc. shares in Q2 2015, an estimated $407K.
  • Passport Capital first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 3 quarters.
  • Passport Capital's Orexigen Therapeutics, Inc. position peaked at $4.6M in Q3 2013.
  • 161 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2015.

Based on Passport Capital's 13F filing for Q2 2015, filed 14 Aug 2015.